Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Company Overview - Beam Therapeutics is a next-generation gene editing company utilizing a modified form of CRISPR known as base editing, which allows for precise single base changes in the genome without causing double-stranded breaks [1][2] - The technology offers improved precision and predictability in therapeutic outcomes, aiming for durable one-time therapies for serious diseases [2] Core Areas of Focus - The company primarily focuses on two core franchises, with a significant emphasis on hematology, where blood cells are edited directly to potentially cure diseases [2] - One of the lead programs is targeting sickle cell disease, showcasing the application of their gene editing technology in treating specific blood disorders [2]